Evidence map›Paper›PMID 38352476›Full record

ArticlebioRxiv : the preprint server for biology2024

Mimicking the breast metastatic microenvironment: characterization of a novel syngeneic model of HER2

Aaron G Baugh, Edgar Gonzalez, Valerie H Narumi, Jesse Kreger, Yingtong Liu, Christine Rafie, Sofi Castanon, Julie Jang, Luciane T Kagohara, Dimitra P Anastasiadou and 7 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Aaron G BaughDepartment of Medicine, Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID 0000-0001-8763-509X
Edgar GonzalezDepartment of Medicine, Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Valerie H NarumiDepartment of Biochemistry and Molecular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Jesse KregerDepartment of Quantitative and Computational Biology, University of Southern California, Los Angeles, CA, USA.ORCID 0000-0001-6438-171X
Yingtong LiuDepartment of Quantitative and Computational Biology, University of Southern California, Los Angeles, CA, USA.
Christine RafieUniversity of Miami Miller School of Medicine, Miami, FL, USA.
Sofi CastanonDepartment of Medicine, Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Julie JangDepartment of Medicine, Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Luciane T KagoharaJohns Hopkins Bloomberg Kimmel Institute for Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Cellular and Molecular Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Dimitra P AnastasiadouDepartment of Microbiology & Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.
James LeathermanJohns Hopkins Bloomberg Kimmel Institute for Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Cellular and Molecular Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Todd D ArmstrongJohns Hopkins Bloomberg Kimmel Institute for Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Cellular and Molecular Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Isaac ChanDepartment of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
George S KaragiannisDepartment of Microbiology & Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.
Elizabeth M JaffeeJohns Hopkins Bloomberg Kimmel Institute for Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Cellular and Molecular Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Adam MacLeanDepartment of Quantitative and Computational Biology, University of Southern California, Los Angeles, CA, USA.ORCID 0000-0003-0689-7907
Evanthia T Roussos TorresDepartment of Medicine, Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID 0000-0002-0740-5102
University of Southern California · USBloomberg (United States) · USAlbert Einstein College of Medicine · USThe University of Texas Southwestern Medical Center · USUniversity of Miami · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI Ulrich Steidl · 1985 to 2026
$111.2M
Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI THOMPSON, ELIZABETH D · 1993 to 2022
$54.6M
(PQB-3) Driver gene-induced inflammation in pancreatic cancer developmentR01CA184926 · NCI · JOHNS HOPKINS UNIVERSITY · PI JAFFEE, ELIZABETH M. · 2014 to 2017
$3.1M
Dynamical Models of Cetuximab Resistance in HNSCC Based on Serial Genomics DataR01CA177669 · NCI · JOHNS HOPKINS UNIVERSITY · PI FERTIG, ELANA · 2014 to 2019
$1.8M
Prometastatic Effects of Neoadjuvant Chemotherapy in Breast CancerR00CA237851 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI KARAGIANNIS, GEORGE S · 2022 to 2024
$745k
High Speed, High Resolution Slide Scanner for Research in Translational MedicineS10OD026852 · OD · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI CONDEELIS, JOHN S · 2022 to 2022
$472k
NCI NIH HHS P30 CA013330NCI NIH HHS P30 CA014089NCI NIH HHS P50 CA062924NCI NIH HHS R00 CA237851NCI NIH HHS R01 CA177669NCI NIH HHS R01 CA184926NIH HHS S10 OD026852
6 · The paper itself

Abstract

Preclinical murine models in which primary tumors spontaneously metastasize to distant organs are valuable tools to study metastatic progression and novel cancer treatment combinations. Here, we characterize a novel syngeneic murine breast tumor cell line, NT2.5-lung metastasis (-LM), that provides a model of spontaneously metastatic neu-expressing breast cancer with quicker onset of widespread metastases after orthotopic mammary implantation in immune-competent NeuN mice. Within one week of orthotopic implantation of NT2.5-LM in NeuN mice, distant metastases can be observed in the lungs. Within four weeks, metastases are also observed in the bones, spleen, colon, and liver. Metastases are rapidly growing, proliferative, and responsive to HER2-directed therapy. We demonstrate altered expression of markers of epithelial-to-mesenchymal transition (EMT) and enrichment in EMT-regulating pathways, suggestive of their enhanced metastatic potential. The new NT2.5-LM model provides more rapid and spontaneous development of widespread metastases. Besides investigating mechanisms of metastatic progression, this new model may be used for the rationalized development of novel therapeutic interventions and assessment of therapeutic responses targeting distant visceral metastases.

Indexed as

Breast cancercancer cell linescancer metastasismouse modelspre-clinical modelssyngeneic models

Identifiers

PMID38352476
PMCPMC10862766
OpenAlexW4391345946

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.